On January 9, 2020 Physicians’ Education Resource (PER), a leading resource for continuing medical education, reported that it will host the 2nd Annual Precision Medicine Symposium: An Illustrated Tumor Board (Press release, Physicians’ Education Resource, JAN 9, 2020, View Source [SID1234552942]). The dynamic symposium will take place April 17-18 at InterContinental New York Barclay in New York City and will be chaired by Andre H. Goy, M.D., chairman, executive director, and lymphoma division chief at John Theurer Cancer Center at Hackensack University Medical Center; and chief science officer and director of research and innovation at Regional Cancer Care Associates in Hackensack.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We look forward to hosting our precision medicine conference for the second year in a row," said Phil Talamo, president of PER. "This meeting is designed to take a targeted approach to treatment, focusing on how biomarkers and testing strategies can personalize care to patients, often times in a tumor agnostic setting."
Across a two-day, pan-tumor symposium, expert faculty will cover the latest topics in solid and liquid tumors, including lung, breast, gastrointestinal, genitourinary, skin cancers and hematologic malignancies. The educational meeting will feature high-impact sessions and keynote lectures that will focus on practical takeaways regarding the latest updates in next-generation sequencing, liquid biopsy and cytogenetic testing. The program will review updates in targeted treatment, including tumor-agnostic indications based solely on genomic markers and other biomarkers. The tumor board overall will emphasize the role of advanced genetic panel testing and the use of targeted therapies, with a focus on data that is most relevant to patient care.